{"id":"W4395109358","doi":"10.1093/ehjcvp/pvae025","title":"Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation","year":2024,"lang":"en","type":"review","venue":"European Heart Journal - Cardiovascular Pharmacotherapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian VIGOUR Centre; University of Toronto; Sanofi (Canada); University of Alberta; St. Michael's Hospital","funders":"Duke Clinical Research Institute; American Regent; St. Jude Medical; Esperion Therapeutics; Idorsia Pharmaceuticals; Servier; MyoKardia; Novo Nordisk; Daiichi-Sankyo; Regado Biosciences; Belvoir Media Group; AstraZeneca; Amarin Corporation; National Institutes of Health; Regeneron Pharmaceuticals; Boston VA Research Institute; Boston Scientific Corporation; Pfizer; York University; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; University of Toronto; Heart and Stroke Foundation of Canada; HLS Therapeutics; GlaxoSmithKline; Amgen; Sanofi; American Heart Association","keywords":"Alirocumab; PCSK9; Medicine; Internal medicine; LDL receptor; Cholesterol; Total cholesterol","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003348731,0.000694991,0.002921096,0.001094095,0.0001329345,0.0007190121,0.0006898607,0.0006675342,0.001348587],"category_scores_gemma":[0.00361387,0.0002614918,0.001658449,0.001581419,0.0002332735,0.0004439056,0.0003752037,0.001039495,0.0003651771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006510905,"about_ca_system_score_gemma":0.001154061,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001193413,"about_ca_topic_score_gemma":0.001955928,"domain_scores_codex":[0.9990915,0.0002911338,0.0001749529,0.0001026679,0.0002838981,0.00005584462],"domain_scores_gemma":[0.9977036,0.001407514,0.0004587326,0.00004301201,0.0003282888,0.00005890971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002451787,0.00009654294,0.001427125,0.04914064,0.003377341,0.0001200497,0.0000965631,0.0005177967,0.0007826063,0.0006928197,0.007112774,0.9341839],"study_design_scores_gemma":[0.005125988,0.009646648,0.08681992,0.0827041,0.04279011,0.004018905,0.0003919055,0.001370541,0.003489444,0.00292513,0.7604447,0.0002725855],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001533446,0.9978243,0.0000654776,0.0001364628,0.00003698187,0.000009892827,0.0000647691,0.000002993117,0.0003257327],"genre_scores_gemma":[0.01088206,0.9884135,0.0001093657,0.0001867294,0.00007818702,0.00002291432,0.0001394657,0.000002500431,0.0001652804],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003348731,"threshold_uncertainty_score":0.01771003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05757911266128796,"score_gpt":0.325943084739561,"score_spread":0.2683639720782731,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}